CORT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
256.1M
+55.3%
164.9M
-18.4%
202.1M
-2.7%
207.6M
+6.8%
194.4M
Cost of Revenue
4.1M
+40.9%
2.9M
+13.3%
2.5M
-44.6%
4.6M
+33.9%
3.4M
Gross Profit
252.1M
+55.6%
162.0M
-18.8%
199.6M
-1.7%
203.0M
+6.3%
191.0M
Operating Expenses
210.8M
-0.4%
211.6M
+8.5%
195.1M
+1.2%
192.8M
+17.3%
164.3M
R&D
53.9M
-18.7%
66.3M
+2.2%
64.9M
-5.8%
68.8M
+13.8%
60.5M
SG&A
156.9M
+7.9%
145.4M
+11.6%
130.2M
+5.0%
124.0M
+19.4%
103.9M
Operating Income
41.3M
+183.3%
-49601000
-1205.4%
4.5M
-56.1%
10.2M
-61.7%
26.7M
EBITDA
42.2M
+186.0%
-49003000
-1126.0%
4.8M
-54.5%
10.5M
-61.3%
27.1M
Net Income
43.0M
+235.3%
-31761000
-230.8%
24.3M
+23.5%
19.7M
-44.0%
35.1M
EPS (Basic)
$0.40
+233.3%
$-0.30
-230.4%
$0.23
+21.1%
$0.19
-42.4%
$0.33
EPS (Diluted)
$0.36
+220.0%
$-0.30
-250.0%
$0.20
+25.0%
$0.16
-44.8%
$0.29
Shares (Diluted)
118.4M
+13.4%
104.4M
-13.1%
120.2M
+0.6%
119.4M
-0.9%
120.5M
Corcept Therapeutics (CORT) โ€” Financials